Rare types of helper T cells uncovered
Researchers have created a new T cell atlas which could aid the development of novel drug therapies for immune-mediated diseases.
List view / Grid view
Researchers have created a new T cell atlas which could aid the development of novel drug therapies for immune-mediated diseases.
Scientists have discovered that each rheumatoid arthritis patient possesses a unique and diverse set of ACPAs.
Researchers found that resolvinT4 restores protective macrophage biological activities in rheumatoid arthritis patients.
A technique that can sort millions of CRISPR-edited cells based on their secretion patterns has been developed to treat autoimmune diseases.
Six types of inflammation with various cell types and disease pathways identified may provide better treatment of rheumatoid arthritis.
An AI strategy developed by US scientists could accelerate the development of new antibody drugs.
The researchers explored the possibility of using the probiotic bacteria Lactobacillus reuteri as a novel oral drug delivery platform to treat rheumatoid arthritis in an animal model.
Trinity College Dublin has developed a new technique that accurately determines the state of macrophages.
The novel screening technique can identify molecules that can disable dangerous proteins before they cause diseases by blocking them from interacting with a cell’s DNA.
A new study links tumour necrosis factor seen in rheumatoid arthritis with T cell dysfunction, potentially leading to new therapies.
A protein-based vaccine has proven a promising option to prevent rheumatoid arthritis, improving bone quality in animal models.
Scientists at the New York University (NYU) Abu Dhabi have used nuclear magnetic resonance (NMR) techniques to determine the structure of a specific nanobody, Nb23. Drug Target Review’s Victoria Rees spoke with lead researcher Professor Gennaro Esposito to find out how their findings could lead to a better understanding of…
New genomic study reveals that the microbiome could predict rheumatoid arthritis prognosis, potentially advancing treatments.
Dr James Woody discusses off-patent indications for anti-TNF to address unmet patient needs in pain, inflammation and beyond.
Dr H. Michael Shepard, CEO and CSO of Enosi Life Sciences, discusses the similarities between cancer and autoimmune diseases, highlighting how this knowledge could be used to enhance treatments.